EUÀÇ µðÁöÅÐ ¹é½Å Á¢Á¾ ¿©±ÇÀ̳ª ¿µ±¹ÀÇ NHS COVID Pass ¾Û µîÀº À¯·´ÀÇ ¾ÈÀüÇÑ Àç°³¿Í COVID-19ÀÇ ¿ì·ÁµÇ´Â º¯ÀÌü ±Øº¹¿¡ ÀÏÁ¤ÇÑ È¿°ú°¡ ÀÖÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹é½Å Á¢Á¾Àº ºü¸¥ ¼Óµµ·Î ÁøÇàµÇ°í ÀÖÁö¸¸, Ä·ÆäÀÎÀÇ ÇâÈÄ µ¿ÇâÀ» Á¿ìÇÏ´Â ¿äÀÎÀ¸·Î¼´Â Á¤Ä¡Àû/Á¾±³Àû »óȲ, ¹é½ÅÀÇ °¡¿ë¼º°ú ¾×¼¼½º, ƯÈ÷ ÀþÀºÃþÀÇ ¹é½Å Á¢Á¾ ÁÖÀú µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ºÒ°¡¸®¾Æ, ·ç¸¶´Ï¾Æ, ¶óÆ®ºñ¾Æ¿¡¼´Â ÁßÀ¯·´/µ¿À¯·´(CEE)ÀÇ ³·Àº ¹é½Å Á¢Á¾·üÀÌ COVID-19 ±ÞÁõ(ƯÈ÷ µ¨Å¸ÁÖ)¿¡ ¹ÚÂ÷¸¦ °¡Çϸç ÀÇ·á À§±â¸¦ ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.
EUÀÇ COVID-19 ¹é½Å ¹× Ä¡·áÁ¦(COVID-19 Vaccine and Therapeutics) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, Àü·«Àû Çʼö ¿ä°Ç, ¼ºÀå ±âȸ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¸ñÂ÷
Àü·«Àû Çʼö ¿ä°Ç
- ¼ºÀåÀÌ ´õ ¾î·Á¿öÁö´Â ÀÌÀ¯
- Àü·«Àû Çʼö ¿ä°Ç
- EUÀÇ COVID-19 ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇÑ »óÀ§ 3°³ Àü·«Àû Çʼö ¿ä°ÇÀÇ ¿µÇâ
- ¼ºÀå ±âȸ°¡ ¼ºÀå ÆÄÀÌÇÁ¶óÀÎ ¿£ÁøÀ» °¡¼Ó
¹é½Å ¹× Ä¡·áÁ¦ ÇÏÀ̶óÀÌÆ®
- ÇÏÀ̶óÀÌÆ®
- COVID-19 ¹é½Å Á¢Á¾ÀÇ Áö¿ªÀû ¿µÇâ
¼ºÀå ±âȸ ºÐ¼®
- ºÐ¼® ¹üÀ§
- COVID-19 ÆÒµ¥¹Í¿¡¼ÀÇ È¸º¹À» À§ÇÑ ¼ºÀå ÃËÁø¿äÀÎ
- COVID-19 ÆÒµ¥¹Í¿¡¼ÀÇ È¸º¹À» À§ÇÑ ¼ºÀå ¾ïÁ¦¿äÀÎ
¼¼°èÀÇ COVID-19 ¹é½Å ¿¬±¸°³¹ß »óȲ
- COVID-19 ¹é½Å ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
- ¼¼°èÀûÀ¸·Î ÀÎÁõµÈ ÁÖ¿ä COVID-19 ¹é½Å °³¿ä
- Phase IIIÀÇ ¼±ÅÃµÈ ¹é½Å Èĺ¸
¼¼°èÀÇ COVID-19 Ä¡·áÁ¦ ¿¬±¸°³¹ß »óȲ
- °³¹ß Èı⠴ܰèÀÇ Áß¿ä ÀúºÐÀÚ(Ç×¹ÙÀÌ·¯½ºÁ¦ ¹× ¸é¿ªÁ¶ÀýÁ¦)
- °³¹ß Èı⠴ܰèÀÇ ÁÖ¿ä mAb
- EUÀÇ COVID-19 Ä¡·áÁ¦ °³¿ä
¼¼°è ³×Æ®¿öÅ©¸¦ È®´ëÇϱâ À§ÇÑ ¹é½Å Á¦Á¶¾÷üÀÇ Àü·«
- Pfizer/BioNTech Vaccines
- Moderna
- J£¦J
- Oxford/AZ
- Novavax
EUÀÇ COVID-19 ¹é½Å Á¢Á¾ Àü°³
- È®º¸µÈ ¿ë·®
- Á¦Á¶¾÷üº° COVID-19 ¹é½Å Á¢Á¾·® ºÐÆ÷
- COVID-19¿¡ ´ëÇØ ¿ÏÀüÇÏ°Ô ¿¹¹æÁ¢Á¾À» ¹ÞÀº ¼ºÀÎ ºñÀ²
- ¼±ÅÃµÈ ±¹°¡¿¡¼ Åõ¿©µÈ COVID-19 ¹é½Å Á¢Á¾ ¿ë·®
- µ¶ÀÏ - 1Â÷ Á¢Á¾ 70%ÀÇ ¸¶ÀϽºÅæ¿¡ ±ÙÁ¢
- ÇÁ¶û½º - Àα¸ÀÇ 70% ÀÌ»óÀÌ ¿ÏÀüÇÏ°Ô ¹é½Å Á¢Á¾
- ÀÌÅ»¸®¾Æ - 1Â÷ Á¢Á¾ 70%ÀÇ ¸¶ÀϽºÅæ¿¡ µµ´Þ
- ¿µ±¹ - 1Â÷ Á¢Á¾ 70%ÀÇ ¸¶ÀϽºÅæ¿¡ µµ´ÞÇÑ À¯·´ ÃÖÃÊ ±¹°¡
- ¼º°øÇÑ ¿µ±¹¿¡¼ÀÇ Àü°³ ¹èÈÄ¿¡ ÀÖ´Â °Í
- DHL Express Çãºê ¹× °ÔÀÌÆ®¿þÀÌ ¸ðµ¨
COVID-19¿ÍÀÇ ½Î¿ò¿¡¼ µðÁöÅÐ ±â¼úÀÇ ¿ªÇÒ
- µ¥ÀÌÅÍ °ü¸®, ¹é½Å Á¢Á¾ ¹× COVID-19·ÎºÎÅÍÀÇ È¸º¹À» °¡´ÉÇÏ°Ô ÇÏ´Â µðÁöÅÐ ±â¼ú Ç÷§Æû
- EUÀÇ COVID-19 Áõ¸í¼/Çコ ÆÐ½º
- IBM µðÁöÅÐ Çコ ÆÐ½º
¼ºÀå ±âȸ ¿µ¿ª
- ¼ºÀå ±âȸ 1 - ¸é¿ª ¾àÈ ¹× ¹ÙÀÌ·¯½º º¯ÀÌü¿¡ ´ëÇÑ Ãß°¡ Á¢Á¾ ¹× ºÎ½ºÅÍ Á¢Á¾
- ¼ºÀå ±âȸ 2 - COVID-19 ¹é½ÅÀÇ ±Û·Î¹ú °ø±ÞÀ» ÁÖµµÇϱâ À§ÇÑ ±¹³» Á¦Á¶ °È
- ¼ºÀå ±âȸ 3 - °¢±¹ÀÇ COVID-19 Çコ ÆÐ½º¸¦ ÀνÄ/°ËÁõÇϱâ À§ÇÑ ±Û·Î¹ú Ç¥ÁØ ¼Ö·ç¼Ç
- Àü½Ã ¸ñ·Ï
- ¸éÃ¥»çÇ×
LSH 22.01.10
Future Growth Potential Driven by Capabilities and Expertise in Vaccine Manufacturing
With this research service, Frost & Sullivan's Healthcare and Life Sciences team provides critical insights into the European Union and UK COVID-19 vaccine and therapeutics market. The report analyzes COVID-19 vaccines and therapeutics in development and delves into supply chain considerations and requirements to manage distribution. Importantly, the study identifies actionable growth opportunities for industry participants. Like the United States, the European Union received criticism for vaccine nationalism, but it is taking steps to encourage global vaccine access. It has launched the Team Europe initiative for improving manufacturing and access to vaccines, medicines, and health technologies in Africa.
Initiatives such as the EU Digital Vaccination Passport and UK NHS COVID Pass app will help Europe in safe reopening and overcoming COVID-19 variants of concern to a certain extent. Although vaccinations are progressing at a fast pace, factors that will determine campaigns' future course include political and religious situations, vaccine availability and access, and vaccine hesitancy specifically in younger population groups. The low vaccination rate in Central and Eastern Europe (CEE) is fueling another COVID-19 surge (especially because of the Delta variant) and causing a healthcare crisis in Bulgaria, Romania and Latvia.
Topics covered include:
- Analyses of COVID-19 vaccines and therapeutics
- Strategies of vaccine manufacturers to scale up their global manufacturing network
- COVID-19 vaccination rollouts
- The role of digital technology in the COVID-19 battle
- The Growth Opportunity Universe
Table of Contents
Strategic Imperatives
- Why is it Increasingly Difficult to Grow?
- The Strategic Imperative 8™
- The Impact of the Top Three Strategic Imperatives for the EU COVID-19 Vaccine and Therapeutics Market
- Growth Opportunities Fuel the Growth Pipeline Engine™
Vaccine and Therapeutics Highlights
- Highlights
- Regional Impact of COVID-19 Vaccinations
Growth Opportunity Analysis
- Scope of Analysis
- Growth Drivers for Recovery from the COVID-19 Pandemic
- Growth Restraints for Recovery from the COVID-19 Pandemic
Global COVID-19 Vaccine R&D Landscape
- COVID-19 Vaccine Pipeline Analysis
- Overview of Key Authorized COVID-19 Vaccines Globally
- Selected Vaccine Candidates in Phase III
Global COVID-19 Therapeutic R&D Landscape
- Key Small Molecules in Late Stage of Development (Antivirals and Immunomodulators)
- Key mAbs in Late Stage of Development
- EU COVID-19 Therapeutics Snapshot
Vaccine Manufacturer Strategies to Scale Up Their Global Network
- Pfizer/BioNTech Vaccines
- Moderna
- J&J
- Oxford/AZ
- Novavax
EU COVID-19 Vaccination Rollout
- Capacity Secured
- Distribution of COVID-19 Vaccine Doses by Manufacturer
- Percentage of Adults Fully Vaccinated Against COVID-19
- COVID-19 Vaccination Doses Administered in Selected Countries
- Germany-Approaching the 70% First-dose Milestone
- France-More than 70% of the Population Fully Vaccinated
- Italy-Reached the 70% First-dose Milestone
- UK-First European Country to Reach the 70% First-dose Milestone
- Behind the Successful UK Rollout
- DHL Express Hub and Gateway Model
Role of Digital Technology in the COVID-19 Fight
- Digital Technology Platforms Enabling Data Management, Vaccination, and Rebounding from COVID-19
- EU COVID-19 Certificate/Health Pass
- IBM Digital Health Pass
Growth Opportunity Universe
- Growth Opportunity 1-Additional and Booster Doses for Waning Immunity and Emerging Virus Variants
- Growth Opportunity 1-Additional and (continued)
- Growth Opportunity 2-Strengthening Domestic Manufacturing for Leading Global Supply of COVID-19 Vaccine
- Growth Opportunity 2-Strengthening Domestic Manufacturing for Leading Global Supply of COVID-19 Vaccine (continued)
- Growth Opportunity 3-Global Standard Solution for Recognising and Verifying Individual Countries' COVID-19 Health Pass
- Growth Opportunity 3-Global Standard Solution for Recognising and Verifying Individual Countries' COVID-19 Health Pass (continued)
- List of Exhibits
- List of Exhibits (continued)
- Legal Disclaimer